Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease

被引：61

作者：

Chrusciel, Piotr ^{[1
]}

Rysz, Jacek ^{[2
]}

Banach, Maciej ^{[1
]}

机构：

[1] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Hypertens, PL-90549 Lodz, Poland

[2] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Nephrol Hypertens & Family Med, PL-90549 Lodz, Poland

来源：

DRUGS | 2014年 / 74卷 / 09期

关键词：

FATTY-ACID OXIDATION; ACUTE MYOCARDIAL-INFARCTION; STABLE ANGINA-PECTORIS; ISCHEMIC CARDIOMYOPATHY; DOUBLE-BLIND; INTERMITTENT CLAUDICATION; DILATED CARDIOMYOPATHY; COMBINATION TREATMENT; ENERGY-METABOLISM; DYSFUNCTIONAL HDL;

D O I：

10.1007/s40265-014-0233-5

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Trimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in patients with stable ischemic heart disease, has been the source of much controversy in recent years; some have gone so far as to treat the medication as a 'placebo drug' whose new side effects, such as Parkinsonian symptoms, outweigh its benefits. This article is an attempt to present the recent key studies, including meta-analyses, on the use of trimetazidine in chronic heart failure, also in patients with diabetes mellitus and arrhythmia, as well as in peripheral artery disease. This paper also includes the most recent European Society of Cardiology guidelines, including those of 2013, on the use of trimetazidine in cardiovascular disease.

引用

页码：971 / 980

页数：10

共 71 条

[1] Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH):: randomised, double-blind, placebo-controlled trial [J].

Anand, I ;

McMurray, J ;

Cohn, JN ;

Konstam, MA ;

Notter, T ;

Quitzau, K ;

Ruschitzka, F ;

Lüscher, TF .

LANCET, 2004, 364 (9431) :347-354

[2] Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury [J].

Argaud, L ;

Gomez, L ;

Gateau-Roesch, O ;

Couture-Lepetit, E ;

Loufouat, J ;

Robert, D ;

Ovize, M .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2005, 39 (06) :893-899

[3]

Athyros VG, 2011, ARCH MED SCI, V7, P1067, DOI [10.5114/AOMS.2011.26621, 10.5114/aoms.2011.26621]

[4]

Banach M, 2006, ROLE TRIMETAZIDINE T

[5] The Role of Trimetazidine After Acute Myocardial Infarction [J].

Banach, Maciej ;

Rysz, Jacek ;

Goch, Aleksander ;

Mikhailidis, Dimitri P. ;

Rosano, Giuseppe M. C. .

CURRENT VASCULAR PHARMACOLOGY, 2008, 6 (04) :282-291

[6] Lipid, blood pressure and kidney update 2013 [J].

Banach, Maciej ;

Serban, Corina ;

Aronow, Wilbert S. ;

Rysz, Jacek ;

Dragan, Simona ;

Lerma, Edgar V. ;

Apetrii, Mugurel ;

Covic, Adrian .

INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (05) :947-961

[7] Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure [J].

Barré, J ;

Ledudal, P ;

Oosterhuis, B ;

Brakenhoff, JPG ;

Wilkens, G ;

Sollie, FAE ;

Tran, D .

BIOPHARMACEUTICS & DRUG DISPOSITION, 2003, 24 (04) :159-164

[8] Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality [J].

Barylski, Marcin ;

Toth, Peter P. ;

Nikolic, Dragana ;

Banach, Maciej ;

Rizzo, Manfredi ;

Montalto, Giuseppe .

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 28 (03) :453-461

[9] Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy [J].

Belardinelli, R ;

Purcaro, A .

EUROPEAN HEART JOURNAL, 2001, 22 (23) :2164-2170

[10] Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect [J].

Belardinelli, Romualdo ;

Solenghi, Maridia ;

Volpe, Loretta ;

Purcaro, Augusto .

EUROPEAN HEART JOURNAL, 2007, 28 (09) :1102-1108

← 1 2 3 4 5 6 7 8 →